MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Change in Cash
$11,198K
Free Cash flow
-$18,946K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Share-based compensation expense
Accrued expenses and other curre...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Lease liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-07-31
2026-04-30
2026-01-31
2025-10-31
Net loss
-32,501
-30,227
-29,752
-37,880
Non-cash interest expense
214
136
183
209
Loss on extinguishment of debt
0
0
-488
-
Loss on impairment of assets
0
147
-
-
Non-cash lease expense
-227
-243
-246
-253
Net amortization of premiums (accretion of discounts) on marketable securities
-
-
-
-3,067
Accretion of marketable securities
280
494
-2,054
-
Unrealized foreign currency losses
29
29
-69
25
Share-based compensation expense
7,810
4,145
2,803
2,606
Depreciation of property and equipment
178
180
189
171
Investment tax credit receivable
153
-375
271
217
Prepaid expenses and other assets
-96
1,582
2,422
-1,986
Accounts payable
744
-625
-4,270
3,972
Accrued expenses and other current liabilities
5,042
-2,485
4,386
4,154
Lease liabilities
-294
-282
39
231
Net cash used in operating activities
-18,946
-30,498
-28,903
-24,962
Purchases of property and equipment
0
98
153
437
Purchases of marketable securities
42,379
50,214
169,187
7,748
Proceeds from maturities of marketable securities
72,500
73,950
43,043
48,685
Net cash used in investing activities
30,121
23,638
-126,297
40,500
Proceeds from second amended term loan
0
0
25,000
-
Repayment of amended term loan principal
0
0
23,053
0
Payment of issuance costs associated with second amended term loan
0
-70
615
-
Proceeds from issuance of pre-funded warrants
0
1
23,249
-
Proceeds from public offering
0
0
126,250
-
Payment of issuance cost associated with public offering and pre-funded warrants
0
0
9,448
-
Proceeds from exercise of stock options
23
3
277
1,991
Net cash provided by financing activities
23
74
141,660
1,991
Effect of exchange rate changes on cash and cash equivalents
0
0
1
0
Net decrease in cash and cash equivalents
11,198
-6,786
-13,539
17,529
Cash and cash equivalents at beginning of period
36,613
36,613
50,152
173,004
Cash and cash equivalents at end of period
41,025
29,827
36,613
50,152
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
ENGN Cash Flow Sankey Diagram
Sankey diagram visualizing ENGN cash flow for the period
Proceeds from maturities
of marketable...
$72,500K
(-18.08%↓ Y/Y)
Proceeds from exercise of
stock options
$23K
(-90.09%↓ Y/Y)
Net cash used in
investing activities
$30,121K
(145.89%↑ Y/Y)
Net cash provided by
financing activities
$23K
(104.93%↑ Y/Y)
Canceled cashflow
$42,379K
Net decrease in cash
and cash...
$11,198K
(107.98%↑ Y/Y)
Canceled cashflow
$18,946K
Purchases of marketable
securities
$42,379K
(-72.32%↓ Y/Y)
Share-based compensation
expense
$7,810K
(10.94%↑ Y/Y)
Accrued expenses and
other current...
$5,042K
(592.38%↑ Y/Y)
Accounts payable
$744K
(-23.30%↓ Y/Y)
Non-cash lease expense
-$227K
(-81.60%↓ Y/Y)
Non-cash interest
expense
$214K
(-66.82%↓ Y/Y)
Depreciation of property and
equipment
$178K
(-47.34%↓ Y/Y)
Prepaid expenses and
other assets
-$96K
(-3100.00%↓ Y/Y)
Net cash used in
operating activities
-$18,946K
(74.49%↑ Y/Y)
Canceled cashflow
$14,311K
Net loss
-$32,501K
(59.08%↑ Y/Y)
Lease liabilities
-$294K
(-783.72%↓ Y/Y)
Accretion of marketable
securities
$280K
(-89.41%↓ Y/Y)
Investment tax credit
receivable
$153K
(-59.52%↓ Y/Y)
Unrealized foreign
currency losses
$29K
(203.57%↑ Y/Y)
Buy us a coffee
enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc. (ENGN)